Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$650.06 USD

650.06
796,714

+25.87 (4.14%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $650.31 +0.25 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.

Zacks Equity Research

Cutera, NetEase, West Pharmaceutical, IDEXX Laboratories and Align Tech highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Cutera, NetEase, West Pharmaceutical, IDEXX Laboratories and Align Tech highlighted as Zacks Bull and Bear of the Day

Zacks Equity Research

Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

by Zacks Equity Research

Sector ETF report for PTH

Riya Anand headshot

Bet on These 3 MedTech Growth Stocks for 2021 & Beyond

by Riya Anand

Stocks like West Pharmaceutical Services (WST), IDEXX Laboratories (IDXX) and Align Technology (ALGN) make great picks for the long term.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) for Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED) owing to domestic growth in the spine business and robust demand for the HEDRON line of products.

Zacks Equity Research

Here's Why You Should Retain Walgreens (WBA) Stock for Now

by Zacks Equity Research

Investors are optimistic about Walgreens (WBA), given the strong performance in the International segment and notable product launches.

Zacks Equity Research

Here's Why You Should Retain Inogen (INGN) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Zacks Equity Research

PacBio (PACB) Closes Omniome Buyout, Forays Into San Diego

by Zacks Equity Research

PacBio's (PACB) latest acquisition is expected to deliver a differentiated set of products and applications across a wide spectrum of markets.

Zacks Equity Research

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.

Zacks Equity Research

PerkinElmer (PKI) to Benefit From BioLegend Buyout: Here's How

by Zacks Equity Research

PerkinElmer's (PKI) latest acquisition is likely to expand its life science business and enhance its reagents portfolio.

Zacks Equity Research

Thermo Fisher (TMO) Introduces New Automated Enzyme Analyzers

by Zacks Equity Research

The two new Gallery Enzyme Master systems by Thermo Fisher (TMO) offer enhanced reliable enzyme analysis across several enterprises.

Zacks Equity Research

Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and solid global performance.

Zacks Equity Research

Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for EXKIVITY

by Zacks Equity Research

Thermo Fisher (TMO) gains FDA pre-market approval for Oncomine Dx as companion diagnostic for Takeda's EXKIVITY.

Zacks Equity Research

Here's Why You Should Retain Catalent (CTLT) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.

Zacks Equity Research

Accuray's (ARAY) CyberKnife Favored For Prostate Cancer Treatment

by Zacks Equity Research

Per the PACE trial data, patients treated with Accuray's (ARAY) CyberKnife SBRT are likely to experience lesser bladder-related side effects unlike conventional linear accelerator.

Zacks Equity Research

Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval From MHLW

by Zacks Equity Research

Thermo Fisher's (TMO) Oncomine Dx Target Test has been approved by MHLW as a companion diagnostic for Eli Lilly and Company's selpercatinib.

Zacks Equity Research

Dexcom's (DXCM) G6 CGM Under NIHB Program to Aid More Patients

by Zacks Equity Research

Expanded access to Dexcom's (DXCM) G6 CGM for clients enrolled in NIHB is expected to aid a wider patient pool to better manage their diabetes.

Zacks Equity Research

Here's Why You Should Retain CONMED (CNMD) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Zacks Equity Research

Here's Why You Should Retain Allscripts (MDRX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.

Zacks Equity Research

NextGen's (NXGN) RCM Services Adopted by Coastal Orthopedics

by Zacks Equity Research

NextGen's (NXGN) RCM Services aids Coastal Orthopedics to maintain its financial stability throughout the pandemic period.

Zacks Equity Research

NextGen (NXGN) Reaches 2 Million Telehealth Visit Milestone

by Zacks Equity Research

NextGen (NXGN) reaches a milestone by facilitating 2 million telehealth visits with the NextGen Virtual Visits platform since March 2020.

Zacks Equity Research

Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (IDXX) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Reasons to Hold on to AMN Healthcare (AMN) Stock for Now

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Zacks Equity Research

SmileDirectClub (SDC) Struggles With New Markets, High Debt

by Zacks Equity Research

SmileDirectClub's (SDC) escalating costs and expenses are putting pressure on the bottom line.

Zacks Equity Research

Stryker (SYK) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Stryker's (SYK) strength in robotics and its diversified product portfolio.